Chile's Leading Drugmaker Plans For Growth
In terms of both volume and value of sales, Laboratorio Chile SA is Chile's largest pharmaceutical company, and it is now looking for growth elsewhere, particularly in nearby Argentina and Peru, which have recently opened up their markets to foreign companies.
Laboratorio Chile was established in 1896, nationalized in 1939 and reprivatized in 1988. Last year it made a public offering of 1.8 million American Depository Receipts on the New York Stock Exchange, which increased average trading in the stock three-fold, notes Bear Stearns' David Molowa.
The company's sales in 1993 amounted to approximately $49.5 million, a 3% rise on the previous year. However, due to higher marketing and administrative costs, earnings declined 8% to $7.9 million. For the first nine months of 1994, the latest figures available, Laboratorio Chile saw sales increase 7% to $44.4 million and earnings improve 16% to $8.8 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze